Lung cancer is one of major cancers, and survival of lung cancer patients is dictated by the timely detection and diagnosis. Cell-free circulating miRNAs were proposed as candidate biomarkers for lung cancer. These RNAs are frequently deregulated in lung cancer and can persist in bodily fluids for extended periods of time, shielded from degradation by membrane vesicles and biopolymer complexes. To date, several groups reported the presence of lung tumour-specific subsets of miRNAs in blood. Here we describe the profiling of blood plasma miRNAs in lung cancer patients, healthy individuals and endobronchitis patients using miRCURY LNA miRNA qPCR Serum/Plasma Panel (Exiqon). From 241 ratios differently expressed between cancer patients and healthy individuals 19 miRNAs were selected for verification using the same platform. LASSO-penalized logistic regression model, including 10 miRNA ratios comprised of 14 individual miRNAs discriminated lung cancer patients from both control groups with AUC of 0.979.

中文翻译：

---

肺癌患者和无癌症个体血浆中 179 种 miRNA 表达的分析。


肺癌是主要癌症之一，及时发现和诊断决定了肺癌患者的生存。无细胞循环 miRNA 被提议作为肺癌的候选生物标志物。这些 RNA 在肺癌中经常失调，并且可以在体液中持续较长时间，并且不会被膜囊泡和生物聚合物复合物降解。迄今为止，多个研究小组报告了血液中存在肺肿瘤特异性 miRNA 子集。在这里，我们描述了使用 miRCURY LNA miRNA qPCR 血清/血浆面板 (Exiqon) 对肺癌患者、健康个体和支气管炎患者的血浆 miRNA 进行分析。使用同一平台，从癌症患者和健康个体之间表达不同的 241 个比率中选择了 19 个 miRNA 进行验证。 LASSO 惩罚逻辑回归模型（包括由 14 个单独的 miRNA 组成的 10 个 miRNA 比率）区分了两个对照组的肺癌患者，AUC 为 0.979。